Format

Send to

Choose Destination
Cancer Lett. 2012 Dec 28;325(2):155-64. doi: 10.1016/j.canlet.2012.07.012. Epub 2012 Jul 16.

Increasing the efficacy of tumor cell vaccines by enhancing cross priming.

Author information

1
Department of Pediatrics, University of Minnesota, Minneapolis, 55455, United States.

Abstract

Cancer immunotherapy has been attempted for more than a century, and investment has intensified in the last 20 years. The complexity of the immune system is exemplified by the myriad of immunotherapeutic approaches under investigation. While anti-tumor immunity has been achieved experimentally with multiple effector cells and molecules, particular promise is shown for harnessing the CD8 T cell response. Tumor cell-based vaccines have been employed in hundreds of clinical trials to date and offer several advantages over subunit and peptide vaccines. However, tumor cell-based vaccines, often aimed at cross priming tumor-reactive CD8 T cells, have shown modest success in clinical trials. Here we review the mechanisms of cross priming and discuss strategies to increase the efficacy of tumor cell-based vaccines. A synthesis of recent findings on tissue culture conditions, cell death, and dendritic cell activation reveals promising new avenues for clinical investigation.

PMID:
22809568
PMCID:
PMC3461191
DOI:
10.1016/j.canlet.2012.07.012
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center